Daxor Expands Outpatient Blood Volume Analysis Services in Kansas
Event summary
- Daxor Corporation launched a new outpatient Blood Volume Analysis (BVA) program at a leading healthcare facility in eastern Kansas on July 29, 2026.
- The initiative leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate blood volume measurements within 24 hours without capital equipment or dedicated lab infrastructure.
- The program aims to replace subjective fluid estimation with precise, data-backed decongestion strategies to optimize patient outcomes and prevent readmissions.
- Michael Feldschuh, President and CEO of Daxor Corporation, highlighted the importance of expanding access to outpatient precision diagnostics to break the costly cycle of readmissions.
The big picture
Daxor’s expansion into outpatient care aligns with broader industry trends toward value-based healthcare, where precise diagnostics can reduce readmissions and lower overall system costs. The company’s turnkey model eliminates logistical hurdles for clinicians, potentially accelerating adoption in high-volume cardiology centers. This move positions Daxor to capitalize on the growing demand for objective fluid management solutions.
What we're watching
- Market Expansion
- The pace at which Daxor can replicate this model in other regions will determine its ability to scale outpatient diagnostics.
- Reimbursement Dynamics
- Whether existing reimbursement structures adequately support the adoption of precision diagnostics like BVA.
- Competitive Positioning
- How Daxor’s turnkey model differentiates it from competitors in the blood volume analysis space.